QTI

QT Imaging Holdings, Inc. - 10-Q Summary (Q2 2025)

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2025. QT Imaging Holdings, Inc. is a medical device company developing and commercializing the QT Breast Scanner, a low-frequency sound wave imaging system. The company operates as a single segment focused on the research, development, and commercialization of this technology. As of June 30, 2025, the company had an accumulated deficit of $47.1 million and continues to rely on external financing to fund operations.

Key Financial Metrics

Note: Total debt principal includes the $10.1 million Lynrock Lake Term Loan and $3.85 million in related party notes. Carrying value of long-term debt is significantly lower due to unamortized discounts.

Material Changes vs. Prior Period

• Revenue Growth: Revenue increased 113% year-over-year for the quarter and 110% for the six-month period, driven by the sale of 8 scanners in Q2 2025 (vs. 4 in Q2 2024) and 14 scanners in the first half of 2025 (vs. 7 in 2024). This growth aligns with Minimum Order Quantities (MOQs) under the amended distribution agreement with NXC Imaging.
• Net Loss Expansion: Net loss increased significantly to $15.14 million for the six months ended June 30, 2025, compared to $1.88 million in the prior year period. This was primarily driven by non-cash expenses related to debt issuance and fair value adjustments.
• Debt Restructuring: The company extinguished the Yorkville Note and Cable Car Note in February 2025 using proceeds from a new $10.1 million senior secured term loan (Lynrock Lake Term Loan). This resulted in a $6.64 million loss on issuance and a $2.03 million debt extinguishment loss recorded in the first half of 2025.
• Operating Expenses: Selling, general, and administrative (SG&A) expenses decreased by 50% year-over-year for the six-month period, largely due to the absence of significant transaction expenses incurred in the prior year related to the business combination.

Guidance, Outlook, and Risks

• Liquidity Outlook: Management believes current cash, the $5.4 million net proceeds from the Lynrock Lake Term Loan, recent PIPE investments ($700,000 total), and expected revenue from NXC MOQs ($18.0 million in 2025) are sufficient to fund operations for at least the next 12 months.
• Manufacturing and Distribution: The company entered a manufacturing agreement with Canon Medical Systems to scale production and an amended distribution agreement with NXC Imaging, which includes MOQs expected to generate significant cash inflows in 2025 and 2026.
• Key Risks:
  • Going Concern: The company has a history of net losses and negative cash flows. Continued profitability depends on achieving sufficient revenue to support the cost structure.
  • Customer Concentration: Customer A (NXC Imaging) accounted for 99% of revenue in Q2 2025. Loss of this contract would have a material adverse effect.
  • Dilution: Significant warrant liabilities exist, including 61 million shares issuable to Lynrock Lake and 15 million to Yorkville, which were reclassified to equity in June 2025 but represent substantial potential dilution.
  • Debt Covenants: The Lynrock Lake Term Loan includes mandatory prepayment provisions based on extraordinary receipts, asset sales, and a percentage of accounts receivable collections starting in 2026.

Investor Verification Checklist

• Debt Covenants: Verify the specific triggers for mandatory prepayments under the Lynrock Lake Term Loan, particularly the 15% accounts receivable collection requirement starting January 1, 2026.
• Customer Concentration: Assess the stability of the relationship with NXC Imaging, which represents nearly all current revenue.
• Warrant Liability Reclassification: Confirm the accounting treatment and future dilution impact of the Lynrock Lake and Yorkville warrants reclassified to equity in June 2025.
• Inventory Levels: Review the increase in inventory ($3.23 million) against the pace of sales to ensure no obsolescence risks exist as the company scales manufacturing.
• Related Party Transactions: Monitor the terms of the $3.85 million in related party notes payable and the recent PIPE investments from related parties.